CORRIGAN QUESTION: Ziconotide (Prialt) is administered intrathecally, why not Z160?
Ziconotide (Prialt) is administered intrathecally, why not Z160?
Ziconotide (SNX-111; Prialt) is a non-opioid and non-NSAID analgesic agent used for the amelioration of severe and chronic pain. Derived from Conus magus ("Cone Snail"), it is the synthetic form of an ω-conotoxin peptide. Severe psychiatric symptoms and neurological impairment may occur during treatment with Prialt.
So far, there are no major side effects associated with Z160. It is a small molecule, not a peptide like Prialt. Why not administer Z160 intrathecally, directly to its target, like Prialt, WITHOUT the side effects in especially difficult cases involving opioid breakthrough pain?
Elan's Prialt shows no signs of being addictive, a big advantage over opioids. The drug blocks a calcium channel found at the end of nerve fibers that transmits the pain signal up the spinal cord to the brain. Researchers estimate that it is hundreds of times more potent than morphine, but far more toxic as well, making Prialt an unacceptable candidate for a pill or injection.
Instead, small quantities are pumped directly to the fluid surrounding the spinal cord via an implanted catheter and pump. The FDA restricted Prialt's use to patients with severe pain who no longer get relief from morphine, not a blockbuster-size market. Elan, which has yet to announce pricing, estimates that about 120,000 patients in the U.S. are candidates for Prialt.
Nevertheless, Prialt's approval may pave the way for other pain treatments....LIKE Z160. ZALICUS' Z160 IS PRIALT 2.0 WITHOUT THE SIDE EFFECTS. JAZZ CAN TAKE IT OR LEAVE IT. :)